Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4380961 | 0.88 | CASR (0.38) | CASRTSHRACKR3NPSR1ALDH1A1 | |
| SCHEMBL4385587 | 0.75 | NPSR1 (0.37) | CASRTSHRACKR3NPSR1ALDH1A1 | |
| SCHEMBL4388220 | 0.70 | ESR2 (0.35) | ALDH1A1L3MBTL1 | |
| SCHEMBL4389560 | 0.69 | MTNR1A (0.38) | ALDH1A1L3MBTL1 | |
| SCHEMBL4380957 | 0.67 | ALDH1A1 (0.36) | TSHRACKR3NPSR1ALDH1A1LMNA | |
| SCHEMBL13863025 | 0.64 | HRH3 (0.47) | TSHRNPSR1ALDH1A1LMNAOPRM1 | |
| SCHEMBL22769386 | 0.64 | TSHR (0.44) | TSHRNPSR1L3MBTL1OPRM1OPRD1 | |
| SCHEMBL4394954 | 0.63 | HDAC1 (0.44) | NPSR1ALDH1A1LMNAPKML3MBTL1 | |
| SCHEMBL30095890 | 0.63 | NPSR1 (0.43) | TSHRNPSR1ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL29833839 | 0.63 | MRGPRX1 (0.49) | TSHRNPSR1LMNAUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538241-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070155813-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1704856-A1 | HSP90 FAMILY PROTEIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155813-A1 | Hsp90 family protein inhibitors | HSP90AB1, HEATR1, HSP90AB2P | CASR 2635/4885TSHR 487/4885ACKR3 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.